Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study

Valneva SE VALN reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.
The data show that a booster dose of VLA2001 was well tolerated in previously vaccinated participants with either Pfizer Inc PFE and BioNTech SE BNTX or Moderna Inc MRNA shots.
The data confirm the favorable safety profile of VLA2001 seen across all studies, including in homologous or heterologous booster settings.
However, in this study, an additional booster dose of VLA2001 elicited only a marginally increased neutralizing antibody response, Valneva added.
Also see: France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine.
The company previously reported positive heterologous booster results following primary vaccination with AstraZeneca Plc's AZN vaccine - in August 2022 and positive homologous booster results at the end of December 2021.
Valneva is currently seeking regulatory approval for VLA2001 as a homologous and heterologous booster in AstraZeneca - primed individuals who may support the company deploying its inventory in international markets.
Price Action: VALN shares closed at $12.72 on Friday.
Photo Via Wikimedia Commons